Search Results

Biotech Bay

PeploBio and IncellDX Partner to Launch the First Long COVID Test in the UK and EU

PeploBio and IncellDX are launching the first laboratory developed test in the UK and EU to help diagnose Long COVID, providing doctors with accurate insights into personalised treatment approaches using the incellKINE Long Hauler Index technology.

April 17, 2024

·

1 min read

Business

IncellDx Appoints Todd Pollard as Chief Operating Officer

IncellDx today announced Todd Pollard has joined its executive leadership team as Chief Operating Officer.

December 6, 2021

·

1 min read

Biotech Bay

IncellDx Awarded Patent for Use of CCR5 Antagonist Maraviroc in Treatment of COVID-19

IncellDx today announced it has been granted U.S. Patent No. 11,180, 491 by the U.S. Patent and Trademark Office (“USPTO”) for methods of treating coronaviruses including COVID-19 (the “Patent”).

November 23, 2021

·

1 min read

Biotech Bay

Frontiers in Immunology Publishes New Study Data from IncellDx Supporting a Model for Understanding Long COVID’s Cause

IncellDx, a precision medicine company, today announced the journal Frontiers in Immunology has published a study detailing a framework for understanding the potential mechanism of, and potential treatment for, Post-Acute Sequelae of COVID-19 (PASC), also known as long COVID or long haul COVID.

January 11, 2022

·

3 min read

Policy

IncellDx Awarded PD-L1 Detection and Quantification Patent in Tumor Cells and CTCs

IncellDx, Inc., a global leader in single-cell diagnostics, announces the USPTO has issued patent US10,782,298 to IncellDx.

September 24, 2020

·

1 min read

Drug Development

IncellDx to Study Maraviroc, a CCR5 antagonist, in a COVID-19 Phase 2 Clinical Trial

IncellDx will collaborate on the SARS-CoV2 Clinical Trial NCT04435522 involving Pfizer’s FDA-approved CCR5 antagonist Maraviroc.

October 20, 2020

·

1 min read

Business

IncellDx and MD Biosciences Sign Definitive Agreement for Commercialization of COVID-19/Cytokine Storm Cytokine Panel and CCR5 Receptor Occupancy in US and EU

IncellDx, Inc., a global leader in single-cell diagnostics, announces the signing of an agreement with MD Biosciences, Inc. for the commercialization of novel assays based on IncellDx’s work on diagnostic, prognostic, and therapeutic biomarkers in COVID-19 and other cytokine storm conditions. Under the terms of the agreem

September 15, 2020

·

3 min read

Business

IncellDx’s Chronic COVID Treatment Center Partners with ARISE MD Integrative Medicine & Surgery to Evaluate Novel Therapeutic Approach to Chronic COVID

ncellDx’s Chronic COVID Treatment Center (CCTC) (www.covidlonghaulers.com) and ARISE™ MD Integrative Medicine & Surgery announced today a new partnership to evaluate CCR5 antagonists and statins as a potential therapeutic treatment approach for chronic COVID, also known as long COVID or post-acute sequelae of COVID-19 (PASC).

November 18, 2021

·

3 min read

Business

IncellDx Signs Liquid Biopsy Distribution Agreement with Singapore-based Biolidics, Inc.

IncellDx, Inc. and Biolidics have announced that they have signed a Distribution Agreement for the IncellDx bioINK® PD-L1 CTC Core Kit. Biolidics will distribute the product with the Biolidics’ ClearCell® FX1 System.

December 18, 2019

·

1 min read

Biotech Bay

Factorial Diagnostics, IncellDx Sign Exclusive License for Novel in situ Library Prep for Subsequent Next Generation DNA Sequencing

Factorial Diagnostics and IncellDx announced that they have agreed to terms on an exclusive license and supply agreement for technology that will enable the development of their multi-omic, cancer diagnostic workflow.

August 6, 2020

·

2 min read